<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04865458</url>
  </required_header>
  <id_info>
    <org_study_id>HEC89736-P-01</org_study_id>
    <nct_id>NCT04865458</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies</brief_title>
  <official_title>A Phase I Single Arm,Open-label,Multiple Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety, pharmacokinetics and efficacy of HEC89736 in patients with Relapsed or&#xD;
      Refractory B-cell Hematologic Malignancies&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limited toxicities evaluated with NCI-CTC AE v5.0 after the first dose</measure>
    <time_frame>Dosing started until the 28th day</time_frame>
    <description>Incidence of dose limited toxicities and associated dose of HEC89736</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events evaluated by NCI CTCAE 5.0</measure>
    <time_frame>From the frst dose to within 30 days after the last dose</time_frame>
    <description>Incidence of adverse events and associated dose of HEC89736</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Relapsed or Refractory B-cell Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>HEC89736 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HEC89736 tablets,25 mg, 50 mg, 100 mg, 150 mg, 200 mg, QD, 28 days for each cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HEC89736</intervention_name>
    <description>HEC89736 tablets QD every 28 days for each cycle</description>
    <arm_group_label>HEC89736 treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age is over 18 years old&#xD;
&#xD;
          -  Histologically or cytologically diagnosed patients with recurrent or refractory B-cell&#xD;
             malignancies&#xD;
&#xD;
          -  ECOG performance status (PS) 0 ~ 1&#xD;
&#xD;
          -  Expected survival of &gt; or = 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The use of PI3Ks as the target of anti-tumor drugs progress (due to intolerance group)&#xD;
&#xD;
          -  Received any other anti-cancer treatment within 4 weeks&#xD;
&#xD;
          -  Unable to swallow, chronic diarrhea and intestinal obstruction, there are many factors&#xD;
             that affect drug use and absorption&#xD;
&#xD;
          -  Allergy, or known to have a history of allergy to the drug components&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Jianyong, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Song Yuqing, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiang Yingzhi</last_name>
    <phone>+86 13692244184</phone>
    <email>jiangyingzhi@hec.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Song Yuqing, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li JIanyong, Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 26, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

